secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2026-04-14T23:59:59+00:00
Accession:  0001437749-26-012182
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell appoints two new independent directors; three directors retire effective April 15, 2026
--------------------------------------------------------------------------------

- Bryan Gathagan, Michael Brigham, and Bobbi Jo Brockmann retire from board effective April 15, 2026.
- Gilles Guillemette DVM and Anthony DiMarco Ph.D. elected as new directors effective same date.
- Board moves to 7 members with 6 independent directors; CEO remains only non-independent.
- New Strategy & Technology Committee formed; Guillemette chairs it; DiMarco serves on it.
- Guillemette has 30+ years animal health executive experience; DiMarco 40 years biologics R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774926012182/0001437749-26-012182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774926012182/iccc20260413_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-012182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer